Dr. Tse-Wen Chang, founder and chairman of Immunwork and T-E Meds, shared the latest developments of both companies on 15th January. Immunwork has developed two ultra-long-acting drugs: TE-8105 and TE-8214. TE-8105 primarily targets type 2 diabetes, obesity, and fatty liver disease, and is scheduled to complete Phase 2a clinical trials this year. TE-8214 focuses on
Immunwork 2025 Investor Meeting – Results Presentation Read More »
We are thrilled to announce that T-E Meds has licensed its novel Antibody-Drug Conjugate, TE-1146, to Orient EuroPharma. According to the contract, T-E Meds will receive a signing and licensing fee of NT$270 million (approximately USD 8.5 million) for granting the commercialization rights of the TE-1146 drug in Taiwan, Southeast Asia, New Zealand and the
T-E Meds and Orient EuroPharma Forge Licensing Agreement for TE-1146 Read More »
Immunwork with its “Application of an Innovative Fatty Acid Bundle Platform in the Development of Ultra-Long-Acting Drugs” project, has been honored with the 21st National Innovation Award – Enterprise Innovation Award. This prestigious recognition highlights the excellence of Immunwork’s platform technology and the promising potential drug candidates, earning high acclaim from both national and professional
Immunwork won the 21st National Innovation Award – Enterprise Innovation Award Read More »
The annual Taiwan Healthcare+ Expo will be held from December 5 to 8, 2024, at Hall 1 of the Nangang Exhibition Center. We are honored to be invited to showcase our booth in the InnoZone Innovation Technology Pavilion. You’re welcome to visit us and learn about our latest developments!
We will be participating in the 8th Taiwan Healthcare+ Expo Taiwan. Welcome to visit us Read More »
Dr. Kun-Po Li, the director of business development of Immunwork, will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase during September 24th to 25th, and 27th, 2024. Dr. Li will unravel the innovations behind our cutting-edge therapeutic peptides and ADC platform, highlighting the distinctive “Multi-Arm Linkers.”
Join our presentation at the ACCESS CHINA Partnering Forum Read More »
Immunwork announced that two ultra-long-acting drugs developed using innovative fatty acid bundles technology platform have received approval from the Australian Human Research Ethics Committee in May. TE-8105 targets obesity (including weight management), type 2 diabetes, and fatty liver disease, while TE-8214 targets neuroendocrine tumors and acromegaly. Both drugs have undergone initial dosing in low-dose subjects,
Dr. Tse Wen Chang, Chairman and CEO of Immunwork, and Dr. Art Hsing-Mao Chu, CEO of T-E Meds, have been invited to World ADC Asia 2024 in Korea. They will share updates on our innovative tech platforms and drug candidates, with a special focus on our ADC technologies. Dr. Chu will present “Exploring ADCs With
Join our presentation at the World ADC Asia 2024 Conference Read More »
The 2024 Tang Prize in Biopharmaceutical Science has cast a spotlight on GLP-1 receptor agonists, sparking a global race among pharmaceutical companies. TE-8105 of Immunwork, an ultra-long-acting GLP-1 drug, is set to initiate its Phase I clinical trial in Australia, promising significant potential for future development! News website link: 1. https://www.chinatimes.com/newspapers/20240624000185-260202?utm_source=iii_news&utm_medium=rss&chdtv 2. https://www.chinatimes.com/newspapers/20240620000187-260202?chdtv
The 2024 Tang Prize is awarded to three scientists for the development of GLP-1 Read More »
Exciting news! Our latest published paper offers promising solutions for multiple myeloma treatment through ADC technology platform! We are thrilled to announce the publication of our paper “An Antibody-Drug Conjugate for Multiple Myeloma Prepared by Multi-Arm Linkers” in the prestigious Advanced Science journal. Led by Dr. Allen Yueh-Hsiang Yu, our Senior Manager of Preclinical Development
Our latest research result is published in Advanced Science Read More »
Our Chairman, Dr. Tse-Wen Chang and VP of R&D, Dr. Hsing-Mao Chu are honored speakers at the prestigious J.P. Morgan Healthcare Conference on Februry 21-22, 2024. Dr. Chang and Dr. Chu will share company updates, provide invaluable perspectives, and introduce revolutionary tech platforms and drug candidates.
Join Our presentation at the prestigious J.P. Morgan Healthcare Conference Read More »
